Skip to main content

Building

A better future

through education, skill development and research

LEARN MORE

Medication Linked to Increased Risk of Inflammatory Bowel Disease

Medications that target tumor necrosis factor alpha (TNFα), a protein involved in inflammation, have revolutionized the management of certain autoimmune diseases, but paradoxically, these agents might provoke the development of other autoimmune conditions.

Wednesday, July 3, 2019 12:01 am EDT
"Perhaps more importantly, this study suggests that inflammatory bowel disease may be one of the auto-immune diseases that can be provoked by anti-TNFα agents. This suggests that there may be a common mechanism of immune dysregulation underpinning these diseases."

Medications that target tumor necrosis factor alpha (TNFα), a protein involved in inflammation, have revolutionized the management of certain autoimmune diseases, but paradoxically, these agents might provoke the development of other autoimmune conditions.

In an Alimentary Pharmacology & Therapeutics study of 17,018 individuals with autoimmune diseases who were treated with anti‐TNFα medications—mostly infliximab, etanercept, and adalimumab—and 63,308 individuals who were not, treatment with etanercept, but not other anti‐TNFα agents, was linked with an elevated risk of developing inflammatory bowel disease: a twofold increased risk of Crohn’s disease and a twofold increased risk of ulcerative colitis.

“This study established that there is an increased risk of developing inflammatory bowel disease in individuals taking etanercept. Recognition of this phenomenon is important for clinicians taking care of these patients,” said lead author Joshua Korzenik, MD, of Brigham and Women’s Hospital, in Boston. “Perhaps more importantly, this study suggests that inflammatory bowel disease may be one of the auto-immune diseases that can be provoked by anti-TNFα agents. This suggests that there may be a common mechanism of immune dysregulation underpinning these diseases.”

Additional Information

Link to Study: https://onlinelibrary.wiley.com/doi/10.1111/apt.15370

About Journal 

Alimentary Pharmacology & Therapeutics is an international journal of gastroenterology and hepatology.

The journal accepts systematic reviews, meta-analyses, randomised controlled trials and original papers concerned with Gastroenterology and Hepatology.

AP&T is particularly interested in therapies and diagnostics, including all aspects of translation from bench to bedside: identification of novel therapeutic targets, epidemiology, clinical trials, drug safety and meta-analyses.

About Wiley

Wiley drives the world forward with research and education. Our scientific, technical, medical, and scholarly journals and our digital learning, certification, and student-lifecycle services and solutions help students, researchers, universities, and corporations to achieve their goals in an ever-changing world. For more than 200 years, we have delivered consistent performance to all of our stakeholders. The Company's website can be accessed at www.wiley.com.

Multimedia Files:

Preview image

Contact:

Penny Smith +44 (0) 1243 770448 (UK)
newsroom@wiley.com

Business Wire NewsHQsm